Bioorganic & Medicinal Chemistry ( IF 3.3 ) Pub Date : 2018-09-08 , DOI: 10.1016/j.bmc.2018.09.005 Tsuyoshi Shinozuka , Tomoharu Tsukada , Kunihiko Fujii , Eri Tokumaru , Kousei Shimada , Yoshiyuki Onishi , Yumi Matsui , Satoko Wakimoto , Masanori Kuroha , Tsuneaki Ogata , Kazushi Araki , Jun Ohsumi , Ryoko Sawamura , Nobuaki Watanabe , Hideki Yamamoto , Kazunori Fujimoto , Yoshiro Tani , Makoto Mori , Jun Tanaka
![]() |
Attempts were made to reduce the lipophilicity of previously synthesized compound (II) for the avoidance of hepatotoxicity. The replacement of the left-hand side benzene with 2-pyridine resulted in the substantial loss of potency. Because poor membrane permeability was responsible for poor potency in vitro, the adjustment of lipophilicity was examined, which resulted in the discovery of dimethyl pyridine derivative (I, DS-6930). In preclinical studies, DS-6930 demonstrated high PPARγ agonist potency with robust plasma glucose reduction. DS-6930 maintained diminished PPARγ-related adverse effects upon toxicological evaluation in vivo, and demonstrated no hepatotoxicity. Cofactor recruitment assay showed that several cofactors, such as RIP140 and PGC1, were significantly recruited, whereas several canonical factors was not affected. This selective cofactor recruitment was caused due to the distinct binding mode of DS-6930. The calcium salt, DS-6930b, which is expected to be an effective inducer of insulin sensitization without edema, could be evaluated clinically in T2DM patients.
中文翻译:
![](https://scdn.x-mol.com/jcss/images/paperTranslation.png)
发现了DS-6930,一种有效的选择性PPARγ调节剂。第二部分:线索优化
为了避免肝毒性,尝试降低先前合成的化合物(II)的亲脂性。用2-吡啶代替左手侧苯导致效力的实质损失。由于差的膜通透性导致体外效价差,因此对亲脂性的调节进行了检查,从而发现了二甲基吡啶衍生物(I,DS-6930)。在临床前研究中,DS-6930表现出较高的PPARγ激动剂效价,且血浆葡萄糖降低明显。DS-6930在体内进行毒理学评估后维持与PPARγ相关的副作用减少,并没有显示出肝毒性。辅助因子募集测定表明,显着募集了一些辅助因子,例如RIP140和PGC1,而几个典型因子并未受到影响。这种选择性辅因子募集是由于DS-6930的独特结合模式引起的。钙盐DS-6930b被认为是有效的胰岛素增敏剂,无水肿,可在T2DM患者中进行临床评估。